EconPapers    
Economics at your fingertips  
 

HTRA1 disaggregates α-synuclein amyloid fibrils and converts them into non-toxic and seeding incompetent species

Sheng Chen, Anuradhika Puri, Braxton Bell, Joseph Fritsche, Hector H. Palacios, Maurie Balch, Macy L. Sprunger, Matthew K. Howard, Jeremy J. Ryan, Jessica N. Haines, Gary J. Patti, Albert A. Davis and Meredith E. Jackrel ()
Additional contact information
Sheng Chen: Washington University
Anuradhika Puri: Washington University
Braxton Bell: Washington University
Joseph Fritsche: Washington University
Hector H. Palacios: Washington University
Maurie Balch: Washington University
Macy L. Sprunger: Washington University
Matthew K. Howard: Washington University
Jeremy J. Ryan: Washington University
Jessica N. Haines: Washington University
Gary J. Patti: Washington University
Albert A. Davis: Washington University
Meredith E. Jackrel: Washington University

Nature Communications, 2024, vol. 15, issue 1, 1-18

Abstract: Abstract Parkinson’s disease (PD) is closely linked to α-synuclein (α-syn) misfolding and accumulation in Lewy bodies. The PDZ serine protease HTRA1 degrades fibrillar tau, which is associated with Alzheimer’s disease, and inactivating mutations to mitochondrial HTRA2 are implicated in PD. Here, we report that HTRA1 inhibits aggregation of α-syn as well as FUS and TDP-43, which are implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The protease domain of HTRA1 is necessary and sufficient for inhibiting aggregation, yet this activity is proteolytically-independent. Further, HTRA1 disaggregates preformed α-syn fibrils, rendering them incapable of seeding aggregation of endogenous α-syn, while reducing HTRA1 expression promotes α-syn seeding. HTRA1 remodels α-syn fibrils by targeting the NAC domain, the key domain catalyzing α-syn amyloidogenesis. Finally, HTRA1 detoxifies α-syn fibrils and prevents formation of hyperphosphorylated α-syn accumulations in primary neurons. Our findings suggest that HTRA1 may be a therapeutic target for a range of neurodegenerative disorders.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-46538-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46538-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-46538-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46538-8